Most Brazilians know Hypera not by its corporate name, but by the medicines in their bathroom cabinet — Buscopan, Neosaldina, Doril. It is the country’s largest listed pure-play pharma company, quietly minting profits from everyday ailments. Full nameHypera S.A. Tickers / exchangeHYPE3 / B3 (Brasil, Bolsa, Balcão) HeadquartersSão Paulo, SP, Brazil SectorHealthcare — Specialty & Generic Drugs Employees10,564 Market valueR$ 14.25 billion (US$ 2.82 billion) Yearly sales (TTM)R$ 8.64 billion (US$ 1.71 billion) Net profit (TTM)R$ 1.20 billion (US$ 236.5 million), 2025-fiscal Net margin19.5% (our calculation) Return on equity12.95% Price-to-earnings7.73 …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
Hypera Q2 Profit Rises 15% To US$96 Million
Hypera Reverses Loss, Posts R$346M Profit as Working Capital Reset Pays Off
Hypera’s Surprise R$1.5 Billion Capital Raise Divides Wall Street and Fuels Pharma M&A Speculation
Brazil’s Supersalaries And Hyperactive Courts: How A Democracy Trips Itself Up
Fleury, Hypera, and Sequoia: Contrasting Fortunes in Brazil’s Healthcare and Logistics Sectors
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →